The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
ice - launching cbd products has tuned the market in for a trip to peace & wakelessness
Michael - have a look at starsailor's post & link about publicity & CBD product launch
we're flying high, high on the CDC - good marketing for a sleep wellness company.
recovery of SP & ability to fund a dividend depends on the underlying P&L IMO.
Sale of Axelos - great! er.. now, how will the contribution it makes to P&L be replaced? dunno
mentioning ODX, I hope we avoid a speeding ticket
keep at eye out for the unit value of the transaction & time - spread may be small but you can usually spot buys at a higher price than the sells at that point in time
This may be wrong, so be warned but is SNG just about Covid?
Isn't it about cytokine storm which can also be in COPD, situations of immuno deficiency, types of asthma, bronchitis, other lung infections from influenza or other types of coronavirus & rhinovirus (even bacterial pneumonia?). Each one may not be as high in public awareness but all are significant if the treatment is effective.
I am hoping SNG can gain approval for benefit in Covid & thereafter have benefit that might otherwise have taken years to reach.
I like JW, I like his enthusiasm & I like lots about his contribution but he got his bugbear about testers wrong just before GDR went 40p-140p, ODX may be producing millions per week, the this baby may well have moved at a stunning pace ahead to just about be able to meet a national threat from (current) Covid mutations. Supposing mutation got worse JW? Where would we run to? --- we know guys, there is only one candidate 4 letters, beginning with N & ending with T
Agree that JW didn't seem to listen to what Vadim had to say about a new normal. JW had decided tests were history because the vaccine has arrived & didn't hear that teh world may be very different indeed.
It might have been better to ask JW whether he had thought if Escape Hunt, an event provider JW is enthusiastic about, would have to test every participant, vaccinated or not. We may have twigged air travel may be different, how about trains, schools, hotels, nursing homes etc.
It was tedious not to consider how many different types of test, with different purposes, there may need to be.
Clause 35 commits Novacyt to the comply with the Official Secrets Acts 1911-1989 & section 2 of Financie Act 1989.
There is also a clause on confidentiality (no 37)
37.1 In respect of any Confidential Information it may receive directly or indirectly from the other Party (“Discloser”)
and subject always to the remainder of Clause 37 of this Schedule 2, each Party (“Recipient”) undertakes to
keep secret and strictly confidential and shall not disclose any such Confidential Information to any third party
without the Discloser’s prior written consent & .... it goes on to state conditions
& this looked relevant
37.4 The Supplier may only disclose the Authority’s Confidential Information, and any other information provided to
the Supplier by the Authority in relation to this Contract, to the Supplier Personnel or professional advisors who
are directly involved in the performance of or advising on the Supplier’s obligations under this Contract.
Daniel Levi has been a more reliable & honest source of market sensitive information about UJO than the RNSs & PR run by the company so why not take note of what he says now?
How much would West Newton be worth to an oil major?
think it is follow on of the announcement by RENX 4 Feb of virtual conference on 11 Feb at which Sara Barrington has a slot.
Key part copied:
American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day
for Kidney Health
Event Featuring Leading Clinicians, Biotech Innovators and Federal Health Agencies
to Highlight Innovation and Opportunity in Kidney Health
NEW YORK, Feb. 4, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney diseases to drive improved patient outcomes and advance value-based care, announced today that it will co-host a Capital Markets Day for Kidney Health with the American Society of Nephrology (ASN) on Thursday, February 11 from 8:00 a.m. - 12:30 p.m. EST. The virtual event will bring together a broad group of delegates representing the kidney community, including leading clinicians, representatives of U.S. government health agencies, kidney care innovators and investors focused on life sciences and medical technology, for a series of presentations and panel discussions on the challenges and innovations arising from kidney health and the market opportunity in this area.
The Capital Markets Day for Kidney Health event will feature keynote addresses by Susan E. Quaggin, MD, FRCP(C), FASN, President, American Society of Nephrology and Chief, Division of Nephrology and Hypertension, Director, Feingberg Cardiovascular and Renal Research Institute, Charles Horace Mayo Professor of Medicine at Northwestern University; and Steven Coca, DO, MS, Associate Professor of Medicine Icahn School of Medicine at Mount Sinai, New York and co-founder of RenalytixAI. RenalytixAI CEO James McCullough will also participate in a panel discussion on lead IPOs in kidney disease in 2020.
The full agenda and registration information can be viewed here: https://www.asn-online.org/KCMD
Kidney diseases affects 850 million individuals worldwide, including over 37 million Americans, costing the U.S. healthcare system over $120 billion per year in Medicare spending alone.1, 2, 3 Despite the significant patient need, awareness and new product development has lagged behind many other fields, until now. There is a trend among healthcare companies, medical providers, organizations, and researchers to assess early-stage prognosis and end-to-end integrated solutions for kidney disease in an effort to prevent the economic and health impacts.
"Better management in kidney disease is happening now, and the roster of speakers today are innovators in their field and at the cutting edge of transforming the way we understand the progression of early-to-end-stage kidney disease," said Susan E. Quaggin, MD. "As we begin to change the consequences of kidney disease for patients through the use of emerging technologies, we expect to begin to see better outcomes for patients as well
Larry
I'll have a look too.
I actually offloaded 40% of my holding when this had me puzzled me but have got over my doubts.
The SP was circa £3 back then. It made me uneasy that there might be a reason that I was unaware of. A continental investment fund was shorting, I wondered shorting was a financial device to protect the value of shares they also held that were not transparent or something else beyond me or indicative of a dividend block etc. I contacted Mandy & the Financial Consultants supporting without solving my doubt. A contributor here had picked the absence of requirement to RNS under the City Code and his comment helped me get myself un-spooked. It is just a difference in this investment & I loaded 40% back in. Incidentally, at the time I also spotted an error & inconsistencies on 3rd party websites in tallies of significant interests so I take their disclosure only as a guide. In other respects corporate governance has seemed protective of us PIs and as responsive as they can possibly be whilst delivering such impressive progress.
Larry - I forgot to say thanks for those links, I'll puzzle over them & how this all stacks up if we don't have an audited disclosure in Financial Statements to go on. KR & GL
Larry - I tracked several holdings through RNSs & found changes that were not RNSd - for instance, if you look through the RNSs during 2019 when Negma converted loan to shares the build up was counted methodically, except from one RNS missing between 23 & 27 Sep 2019 (look at cumulative disclosure) (& not picked up by their company secretarial control) but NO, (nil), reduction was RNSs. If we could rely on RNS's Negma holds 22m shares or 32.4% although that is obviously incorrect.
I dug through what the French code might be & came up with my view of why RNSs on significant holdings are only filed in the UK & not in a complete trail & also why significant shareholdings are not disclosed in the annual Financial Statements & what the disclosure on RNSs that I quoted is about. The Financial Statements have been audited and must meet the disclosure requirements for their filing (in France). This all puzzled me when the share was held down at such a low level.
I now take what financial website disclose with a pinch of salt unless they you can point me to a pile of RNSs that I have missed.
The share register is a French document presumably located technically, not in Camberley, but at the registered office in France. I don't know if it is open to inspection for a "societe anomie" in the way it would be for a limited company in the UK where transparency underpins much the framework for dealings with legal entities.
How can anyone honestly know what IIs hold of NCYT when it's registration under the French Rules does not require it to notify the market of changes in its significant holders as it would under the (UK) City Code that we are used to?
Read the footnote on any RNS if you are not aware of this - I'll copy the paragraph on the RNS filed on 1 Feb on Total Voting Rights for ease of reference
"The total number of ordinary shares in the Company is 70,626,248. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.
Y, track record of shoddy governance, insider trading & double dealing take their toll when positive news comes along & the SP goes down not up like today.
bizeeboi - think that is right & it has to be announced prior to 18 March at the latest & probably with notice before that. The big boys wouldn't hang around without a contractual commitment to see what the client would do. Shall we guess in the next 2 weeks if 7 are left?
tkr - i feel your pain. perhaps PR could be better, they have been a small outfit changing in a massive year. nevertheless release of information is a horses for courses art. They have guessed they'll end up with circa hundreds of millions & worked to secure it whereas AVCT & ODX have bene concerned about approvals. Don't be too down on them, they have managed to rival huge organisations through the brilliance of their technology & acumen. Amazing, despite being fed up with SP today.
I can understand from the mathematics of financial modelling how this share price is an anomaly because the business opportunity is not thought of as being from now until eternity. Perhaps it will turn out to be!
They are obliged to announce information that has a material bearing on share price. We can understand that £10m would be material in some situations but against £300m an announcement might even detract from correctly appreciating the value of the opportunity. I got to a figure of 305m euro for revenue phasing roll out, subtracting delays, adding service and probably lots of luck in compensating errors but what they have told us seemed to stack up.
I hadn't appreciated eastendboy's point about what the roll of phase 2 might be for & have just counted up the hospitals in England, Scotland & Wales - roughly 450 + 194 + 71 = 715. If we knew the second wave was coming in September we might land on numbers like 300 for phase 1 and 700 for phase 2 assuming every hospital would need one and some hospitals more than one.
I think brokers are on top of this to get themselves to to their guide prices.
After a bad day, at last, this seems like good news if NCYT can have the 300 (or whatever the number) extended from 18 March, and a huge bonus if they get a good proportion of the 700 when things calm down. On the other hand, perhaps the good news that isn't factored into todays price will be that their freedom to supply those machines no longer required by the DHSC to other customers.